Initial Results With IMA402, a PRAME-Targeted T-cell Receptor (TCR)- based Bispecific T-cell Engager (TCER) in Advanced Solid Tumors

Targeting PRAME+ Tumors with IMA203CD8, a PRAME-directed TCR T-cell Therapy: Results from a Phase 1 Study